Research
Hormonal
Estrogen receptor alpha (ERα) activation improves insulin sensitivity and glucose tolerance, whereas ERβ activation may have prodiabetogenic effects or reduced efficacy in this context.
Not all estrogen effects are the same. The specific receptor alpha (ERα) is key for improving insulin sensitivity. This suggests that future treatments might focus on targeting this specific receptor to gain metabolic benefits while avoiding other side effects.
GoodQualifiesHIGH confidence
ERα activation with specific agonists reverses high fat diet-(HFD-)induced insulin resistance, whereas ERβ knockout mice display improved insulin sensitivity and glucose tolerance, suggesting that ERα plays a primary role in insulin-glucose homeostasis.
Why this rating
Supported by multiple animal studies (knockout mice, agonist studies) and some human case studies.
Source
Estrogen: An Emerging Regulator of Insulin Action and Mitochondrial Function
Anisha A. Gupte et al. · Journal of Diabetes Research · 2015
DOI 10.1155/2015/916585
narrative_reviewCited 194×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Loss of circulating estrogen (E2) due to menopause causes rapid metabolic changes, including reduced metabolic rate, increased central adiposity, and insulin resistance, primarily mediated by estrogen receptor alpha (ERα).Good
- Estrogen regulates mitochondrial function, including biogenesis and respiratory chain activity, and loss of estrogen leads to mitochondrial dysfunction which contributes to insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →